About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 369 record(s)
Req # A-2021-000561
Adverse Reaction Reports (AERs) for CABAZITAXEL. Report numbers: E2B_03413381, E2B_03413387, 000926786.Organization: Health Canada
September 2021
Req # A-2021-000563
Adverse Reaction Reports (AERs) for ALEMTUZUMAB. Report numbers: E2B_03394016, E2B_03393987, E2B_03387869, E2B_03391239, E2B_03454376, E2B_03387914, E2B_03391267, E2B_03396602, E2B_03387903, E2B_03391347, E2B_03391236, E2B_03393768, E2B_03392200, E2B_03393774, E2B_03391849, E2B_03391274, E2B_03463382, E2B_03468912, E2B_03387890.Organization: Health Canada
September 2021
Req # A-2021-000589
Adverse Reaction Reports (AERs). Report numbers: E2B_03442035, E2B_03625223, 000934948, 000940688, E2B_03037711, E2B_03787485, E2B_03823366.Organization: Health Canada
September 2021
Req # A-2021-000602
The Class II Medical Device known as MEDLY. This product was apparently issued Medical Device Licence No.: 104447 on 2020-03-13. The quality management system (QMS) certificate submitted with the licence application in fulfillment of section 32(2)(f) of the Medical Devices Regulations. Information Requested: copy of the certificate described above.Organization: Health Canada
September 2021
Req # A-2021-000604
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 19-075631-61.Organization: Health Canada
September 2021
Req # A-2021-000622
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-075079-338.Organization: Health Canada
September 2021
Req # A-2021-000634
Adverse Drug Reaction (ADR) for METFORMIN HYDROCHLORIDE. Report number: E2B_03420918.Organization: Health Canada
September 2021
Req # A-2021-000648
Adverse Drug Reaction (ADR) for CANDESARTAN. Report number: E2B_03406743.Organization: Health Canada
September 2021
Req # A-2021-000649
Adverse Drug Reaction (ADR) for CLONAZEPAM. Report number: E2B_03468382.Organization: Health Canada
September 2021
Req # A-2021-000650
Adverse Reaction Reports (AERs) for CYCLOPHOSPHAMIDE. Report numbers: 918864, 918869, 918929.Organization: Health Canada
September 2021